News Tagged ‘GSK

Consumer watchdog urges immediate Avandia ban

Consumer watchdog group Public Citizen released a petition on Thursday calling for an immediate ban on GlaxoSmithKline’s diabetes drug Avandia. In a petition addressed to Commissioner Dr. Von Eschenbach of the U.S. , Public Citizen urged the ban based on trial data revealing the drug’s “multiple, serious risks.”

Read the rest of this entry »

Avandia sales drop hurting GlaxoSmithKline

A UK newspaper reported yesterday that drug giant GlaxoSmithKline (GSK) – the second largest pharmaceutical company in the world – will cut 150 or more scientists and support staff positions.

Read the rest of this entry »

Type 2 diabetes drug Avandia linked to osteoporosis and bone loss

Researchers believe that the drug Avandia may cause bone loss and long-term use may speed up osteoporosis. The thinning of the bones is dangerous and could lead to fatal fractures. The study published in the December 2nd issue of Nature Medicine suggests that usage of rosiglitazone in the treatment of type II may cause osteoporosis.

Read the rest of this entry »

GSK Sent Avandia meta analysis before publication

GlaxoSmithKline’s Avandia is once again making the headlines after it was revealed that the peer reviewer looking at the now-notorious meta-analysis on the diabetes drug’s safety profile leaked a confidential copy of the article to the firm before it was published in the New England Journal of Medicine

Read the rest of this entry »

Two U.S. healthcare providers drop Glaxo’s Avandia

Two U.S. pharmacy benefit managers said on Thursday they had dropped GlaxoSmithKline Plc’s (GSK.L: Quote, Profile, Research) diabetes drug Avandia from their national formularies due to safety concerns.

Read the rest of this entry »

FDA study said to show Avandia risk

The government’s own preliminary evaluation of the pill Avandia confirms the heart risks reported in a study earlier this week and suggests that as many as 60,000 to 100,000 heart attacks might be linked to its use since it came on the market eight years ago, a leading member of Congress said Thursday.

Read the rest of this entry »